What happens when, in the early, uncertain days of a burgeoning global pandemic, you tell investors that you have recurring orders for millions of rapid test kits for $35 million a week for the next six months?  Well, your stock price surges, of course. But what if, before you made that announcement, you had reason to believe that you couldn’t actually obtain the tests after all?  Well, then the SEC halts trading of your stock due to “questions and concerns regarding the adequacy and of publicly available information” about your company.  And it only goes downhill from there. SCWorx Corporation… Read more